Competing Breast Cancer Assays Beat Genomic Health's Oncotype Dx in Canadian Cost Modeling Study
Genomeweb,
NEW YORK – A cost effectiveness analysis published last month by a team of Canadian authors has added another factor to the…
Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer
BioTech Gate,
Findings Show EndoPredict Was Significantly More Cost Effective than Oncotype DX™ SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE…
Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer
NASDAQ,
Findings Show EndoPredict Was Significantly More Cost Effective than Oncotype DX™ SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE…
Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer
Morning Star,
(GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The…